TB Vaccines: The (Human) Challenge Ahead.

about

Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers.Tuberculosis vaccine development: Shifting focus amid increasing development challenges.Zika virus vaccines

P2860

Q30403003-2E142AC5-AF7A-46CF-A2AD-1F9CCF4CE33E Q36256304-8A57F901-62B4-4FE3-82B0-245E6CB99644 Q56354521-F09EA801-F91D-46F1-B9A0-DCD60E4C83C0

P2860

TB Vaccines: The (Human) Challenge Ahead.

Item

http://www.wikidata.org/entity/Q34676075

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

TB Vaccines: The (Human) Challenge Ahead.

@ast

TB Vaccines: The (Human) Challenge Ahead.

@en

TB Vaccines: The

@nl

type

Item

label

TB Vaccines: The (Human) Challenge Ahead.

@ast

TB Vaccines: The (Human) Challenge Ahead.

@en

TB Vaccines: The

@nl

prefLabel

TB Vaccines: The (Human) Challenge Ahead.

@ast

TB Vaccines: The (Human) Challenge Ahead.

@en

TB Vaccines: The

@nl

P1476

TB Vaccines: The (Human) Challenge Ahead.

@en

P2093

David A Hokey

http://www.w3.org/2001/XMLSchema#string

P2860

Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.

Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.

Experience and challenges from clinical trials with malaria vaccines in Africa

Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.

The current state of tuberculosis vaccines

A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin.

Experimental human challenge infections can accelerate clinical malaria vaccine development.

[National surveys of the prevalence of tuberculosis disease--overview, progress and lessons learnt].

Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials.

P304

e128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4172/2161-1068.1000E128

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269715157

http://www.w3.org/2001/XMLSchema#string

P698

25506513

http://www.w3.org/2001/XMLSchema#string

P932

4262929

http://www.w3.org/2001/XMLSchema#string

TB Vaccines: The (Human) Challenge Ahead.

about

P2860

P2860

TB Vaccines: The (Human) Challenge Ahead.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932